BCLI - BrainStorm stock halted as FDA panel reviews ALS therapy NurOwn
2023-09-27 13:58:25 ET
More on BrainStorm Cell Therapeutics
- Brainstorm Cell Therapeutics: I Anticipate A Positive AdCom But There Are Major Risks
- Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2023 Earnings Call Transcript
- Brainstorm falls as FDA posts briefing docs on ALS therapy
- BrainStorm sells 4.05M shares at $1.85 in registered direct offering
- Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics
For further details see:
BrainStorm stock halted as FDA panel reviews ALS therapy NurOwn